Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegeneration and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for JNK2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | JNK2 (MAPK9) Recombinant Protein (Active/Inactive) High purity (>95%), Endotoxin Controlled. Sequence Verified. E. coli/Sf9 Expressed. |
View JNK2 Products |
| Gene Delivery | JNK2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View JNK2 Products |
| Benchmark Ab | Anti-JNK2 Antibody (Clinical clone biosimilar) Recombinant positive control for assay validation. |
View JNK2 Products |
| Validator | JNK2 siRNA Set For knockdown verification. |
View JNK2 Products |
| Related Target A | JNK1 (MAPK8) Isoform selectivity counter-screening to avoid off-target metabolic toxicity. |
View JNK1 Products |
| Related Target B | JNK3 (MAPK10) Isoform selectivity counter-screening for neurodegenerative disease profiles. |
View JNK3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (JNK1 vs JNK2 vs JNK3) | Full panel of human recombinant JNK1/2/3 proteins available with >95% purity verified by SDS-PAGE. |
| Phosphorylation State Control | Kinase-active and unphosphorylated (inactive) states available, sequence-verified to ensure assay reproducibility. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live JNK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for JNK2 therapeutics is intensifying, with major players shifting focus from traditional ATP-competitive pan-JNK inhibitors to highly selective covalent inhibitors and allosteric modulators. As first-generation broad MAPK inhibitors reach clinical limits due to systemic toxicity, the next wave of R&D is targeting isoform-specific JNK2 inhibition to address solid tumors (e.g., triple-negative breast cancer) and chronic inflammatory conditions without disrupting systemic metabolic homeostasis regulated by JNK1.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Covalent) | Bristol Myers Squibb, Merck KGaA | Autoimmune Diseases, Fibrosis | Selectivity Assay (Need high-purity JNK1/2/3 panel) |
| PROTAC / Degrader | Academic spin-offs, Biotech | Oncology (TNBC, HCC) | Target Degradation Validation (Need Lentivirus for stable cell lines) |
| Peptide Inhibitors | Xigen, Aurigene | Neurodegeneration, Ophthalmic | Binding Kinetics & Competition Assay (Need Active Kinase Proteins) |
Title: JNK2/MAPK9 Drug Discovery Landscape & Assay Reagents | TarMart Description: Buy high-purity JNK2/MAPK9 recombinant proteins, biosimilar antibodies, and lentivirus. Analyze clinical trends (isoform selectivity, PROTACs) with our live tracker. Keywords: JNK2 recombinant protein, MAPK9 kinase, JNK inhibitor assay, JNK isoform selectivity, drug discovery reagents.